BiondVax Pharmaceuticals logo

BVXV - BiondVax Pharmaceuticals Share Price

$3.62 0.0  0.0%

Last Trade - 05/03/21

Micro Cap
Market Cap £30.2m
Enterprise Value £39.2m
Revenue £n/a
Position in Universe 5603rd / 6651
Unlock BVXV Revenue
Relative Strength (%)
1m -21.2%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -94.2%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000
Balance Sheet
FINANCIAL BRIEF: : For the nine months ended 30 September 2020,Biondvax Pharmaceuticals Ltd revenues was not reported. Netincome applicable to common stockholders totaled NIS8.6Mvs. loss of NIS66.2M. Net income reflects Financial Incomeincrease from NIS193K to NIS16.5M (income), Financialexpense decrease of 27% to NIS15M (expense). Basic Earningsper Share excluding Extraordinary Items increased from-NIS0.23 to NIS0.01.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for BVXV
Graphical History


BVXV Revenue Unlock BVXV Revenue

Net Income

BVXV Net Income Unlock BVXV Revenue

Normalised EPS

BVXV Normalised EPS Unlock BVXV Revenue

PE Ratio Range

BVXV PE Ratio Range Unlock BVXV Revenue

Dividend Yield Range

BVXV Dividend Yield Range Unlock BVXV Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
BVXV EPS Forecasts Unlock BVXV Revenue
Profile Summary

BiondVax Pharmaceuticals Ltd is an Israel-based is Phase 3 clinical phase biopharmaceutical company. It is developing the M-001 Universal Flu Vaccine. M-001 is undergoing a pivotal, clinical efficacy, Phase 3 trial in about 12,400 participants. M-001 is designed to provide multi-season and multi-strain protection against all human influenza virus strains, both seasonal and pandemic. In 6 completed clinical trials the vaccine was shown to be safe, well tolerated and immunogenic to a broad range of flu strains. The Company’s technology utilizes a proprietary combination of conserved and common peptides from influenza virus proteins to activate both arms of the immune system for a cross-protecting and long-lasting effect.

Last Annual December 31st, 2019
Last Interim September 30th, 2020
Incorporated July 22, 2003
Public Since July 7, 2007
No. of Shareholders: n/a
No. of Employees: 17
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Capital Market
Shares in Issue 11,536,294
Free Float (0.0%)
Eligible for
BVXV Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for BVXV
Upcoming Events for BVXV
Frequently Asked Questions for BiondVax Pharmaceuticals
What is the BiondVax Pharmaceuticals share price?

As of 05/03/21, shares in BiondVax Pharmaceuticals are trading at $3.62, giving the company a market capitalisation of £30.2m. This share price information is delayed by 15 minutes.

How has the BiondVax Pharmaceuticals share price performed this year?

Shares in BiondVax Pharmaceuticals are currently trading at $3.62 and the price has moved by -55.85% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the BiondVax Pharmaceuticals price has moved by -65.18% over the past year.

What are the analyst and broker recommendations for BiondVax Pharmaceuticals?

Of the analysts with advisory recommendations for BiondVax Pharmaceuticals, there are there are currently "buy" , "hold" and "sell" recommendations. The overall consensus recommendation for BiondVax Pharmaceuticals is Not available. You can view the full broker recommendation list by unlocking its StockReport.

When will BiondVax Pharmaceuticals next release its financial results?

BiondVax Pharmaceuticals is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the BiondVax Pharmaceuticals dividend yield?

BiondVax Pharmaceuticals does not currently pay a dividend.

Does BiondVax Pharmaceuticals pay a dividend?

BiondVax Pharmaceuticals does not currently pay a dividend.

When does BiondVax Pharmaceuticals next pay dividends?

BiondVax Pharmaceuticals does not currently pay a dividend.

How do I buy BiondVax Pharmaceuticals shares?

To buy shares in BiondVax Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of BiondVax Pharmaceuticals?

Shares in BiondVax Pharmaceuticals are currently trading at $3.62, giving the company a market capitalisation of £30.2m.

Where are BiondVax Pharmaceuticals shares listed? Where are BiondVax Pharmaceuticals shares listed?

Here are the trading details for BiondVax Pharmaceuticals:

Country of listing: United States
Exchange: NAQ
Ticker Symbol: BVXV
What kind of share is BiondVax Pharmaceuticals?

Based on an overall assessment of its quality, value and momentum, BiondVax Pharmaceuticals is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a BiondVax Pharmaceuticals share price forecast 2021?

Shares in BiondVax Pharmaceuticals are currently priced at $3.62. At that level they are trading at 89.4% discount to the analyst consensus target price of 0.00.

Analysts covering BiondVax Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -0.199704 for the next financial year.

How can I tell whether the BiondVax Pharmaceuticals share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like BiondVax Pharmaceuticals. Over the past six months, the relative strength of its shares against the market has been -91.54%. At the current price of $3.62, shares in BiondVax Pharmaceuticals are trading at -82.06% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the BiondVax Pharmaceuticals PE Ratio?

We were not able to find PE ratio data for BiondVax Pharmaceuticals.

Who are the key directors of BiondVax Pharmaceuticals?

BiondVax Pharmaceuticals's management team is headed by:

Ron Babecoff - CEO
George Lowell - DRC
Tamar Ben-Yedidia - CSO
Yisrael Gewirtz - OTH
Uri Ben-Or - CFO
Jack Rosen - DRC
Mark Germain - CHM
Yael Margolin - DRC
Adi Raviv - DRC
Samuel Moed - DRC
Who are the major shareholders of BiondVax Pharmaceuticals?

Here are the top five shareholders of BiondVax Pharmaceuticals based on the size of their shareholding:

Angels Investments in Hi Tech, Ltd. Corporation
Percentage owned: 30.6% (4.27m shares)
State Street Global Advisors (US) Investment Advisor/Hedge Fund
Percentage owned: 0.51% (71.1k shares)
SPDR Portfolio World ex-US ETF Mutual Fund
Percentage owned: 0.51% (71.2k shares)
Morgan Stanley & Co. LLC Research Firm
Percentage owned: 0.38% (53.2k shares)
ARK Investment Management LLC Investment Advisor
Percentage owned: 0.3% (41.6k shares)
Similar to BVXV
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.